Business
Eli Lilly COVID-19 combo therapy cuts risk of death, hospitalization by 70%, company says – Fox News
A combination of two Eli Lilly antibody drugs were found to reduce risk of hospitalization and death in high-risk patients recently diagnosed with coronavirus by…
A combination of two Eli Lilly antibody drugs were found to reduce risk of hospitalization and death in high-risk patients recently diagnosed with coronavirus by 70%, the company said Tuesday. The results stem from a Phase 3 BLAZE-1 trial involving 1,035 patients and add to previous data collected during Phase 2 trials.
The trial saw patients given 2800 mg of bamlanivimab and 2800 mg of etesevimab. Among the group given the combination therapy, there were 11 “events,” such as hospitalizations, versus…
